Answers are grounded in this paper and cite their sources.
CTX-M enzymes are the predominant extended-spectrum β-lactamases (ESBLs) worldwide, yet local epidemiology in Vietnam remains incompletely characterized. This study investigated CTX-M prevalence among ESBL-producing Escherichia coli from inpatients at a tertiary-care hospital in Ho Chi Minh City and evaluated the diagnostic performance of the NG-Test CTX-M Multi assay. A prospective cross-sectional study was conducted at FV Hospital from January 2024 to April 2025. ESBL-producing E. coli flagged by the VITEK 2 Advanced Expert System (AES) were tested with NG-Test CTX-M Multi (NG Biotech, France). Antimicrobial susceptibility testing followed CLSI M100 guidelines (2024). Diagnostic accuracy was assessed against multiplex real-time PCR (Allplex Entero-DR Assay) in a blinded evaluation of 76 isolates. Of the 461 E. coli isolates, 180 (39.0%) were ESBL producers; CTX-M was detected in 124 (68.9%). CTX-M-positive isolates showed significantly higher resistance to cefotaxime (98.4% vs 28.5%), cefepime (78.2% vs 10.7%), gentamicin (37.9% vs 12.7%), and ciprofloxacin (74.8% vs 73.2%); all P < 0.05. Carbapenems and amikacin retained high susceptibility (>95%) in both groups. CTX-M-positive isolates exhibited broader resistance profiles (≥6 antimicrobial classes: 68.9% vs 27.8%). AmpC flagging was more frequent in CTX-M-negative isolates (69.6% vs 28.2%; P < 0.001). NG-Test CTX-M Multi demonstrated 92.1% sensitivity (95% confidence interval [CI], 79.2–97.3), 94.7% specificity (95% CI, 82.7–98.5), PPV 94.6%, and NPV 92.3%. CTX-M was the dominant ESBL mechanism and was associated with broader multidrug resistance. NG-Test CTX-M Multi showed high diagnostic accuracy, supporting its role as a rapid screening tool; however, larger validation studies are warranted. IMPORTANCE Infections caused by Escherichia coli producing extended-spectrum beta-lactamases (ESBLs) pose a significant challenge for clinical management because they limit the effectiveness of commonly used antibiotics. CTX-M enzymes are now well established as the dominant ESBL determinants worldwide; however, their local prevalence and associated antimicrobial resistance patterns continue to vary across healthcare settings. In this study, we investigated the prevalence of CTX-M-producing E. coli and their resistance profiles in a tertiary care hospital in Vietnam. Our findings demonstrate a substantial burden of CTX-M-associated multidrug resistance affecting both hospital- and community-associated infections. In addition, the evaluation of a rapid lateral flow immunoassay for CTX-M detection highlights its potential role as a practical screening tool to support timely antimicrobial decision-making and infection control efforts. Together, these results provide clinically relevant data to support antimicrobial stewardship and optimize the management of infections caused by resistant E. coli .
No takes yet. Share an insight, caveat, or question.
Loan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: